Toll Free: 1-888-928-9744

Amunix Operating Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Amunix Operating Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Amunix Operating Inc. - Product Pipeline Review - 2015', provides an overview of the Amunix Operating Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amunix Operating Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Amunix Operating Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Amunix Operating Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Amunix Operating Inc.'s pipeline products

Reason to Buy

- Evaluate Amunix Operating Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Amunix Operating Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Amunix Operating Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Amunix Operating Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amunix Operating Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Amunix Operating Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Amunix Operating Inc. Snapshot 5 Amunix Operating Inc. Overview 5 Key Information 5 Key Facts 5 Amunix Operating Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Amunix Operating Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Amunix Operating Inc. - Pipeline Products Glance 12 Amunix Operating Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Amunix Operating Inc. - Drug Profiles 14 AMX-256 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Enfuvirtide-XTEN 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Factor IX-XTEN 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Factor VIIa-XTEN 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Recombinant Protein-1 for Undisclosed Indication 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Recombinant Protein-2 for Undisclosed Indication 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Recombinant Protein-4 for Undisclosed Indication 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Recombinant Protein-5 for Undisclosed Indication 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Recombinant Protein-6 for Undisclosed Indication 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 AMX-179 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Recombinant Protein-3 for Undisclosed Indication 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Protein-7 for Undisclosed Indication 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Recombinant Protein-8 for Undisclosed Indication 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Amunix Operating Inc. - Pipeline Analysis 29 Amunix Operating Inc. - Pipeline Products by Target 29 Amunix Operating Inc. - Pipeline Products by Route of Administration 30 Amunix Operating Inc. - Pipeline Products by Molecule Type 31 Amunix Operating Inc. - Pipeline Products by Mechanism of Action 32 Amunix Operating Inc. - Recent Pipeline Updates 33 Amunix Operating Inc. - Dormant Projects 34 Amunix Operating Inc. - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Amunix Operating Inc. , Key Information 5 Amunix Operating Inc. , Key Facts 5 Amunix Operating Inc. - Pipeline by Indication, 2015 7 Amunix Operating Inc. - Pipeline by Stage of Development, 2015 8 Amunix Operating Inc. - Monotherapy Products in Pipeline, 2015 9 Amunix Operating Inc. - Out-Licensed Products in Pipeline, 2015 10 Amunix Operating Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11 Amunix Operating Inc. - Preclinical, 2015 12 Amunix Operating Inc. - Discovery, 2015 13 Amunix Operating Inc. - Pipeline by Target, 2015 29 Amunix Operating Inc. - Pipeline by Route of Administration, 2015 30 Amunix Operating Inc. - Pipeline by Molecule Type, 2015 31 Amunix Operating Inc. - Pipeline Products by Mechanism of Action, 2015 32 Amunix Operating Inc. - Recent Pipeline Updates, 2015 33 Amunix Operating Inc. - Dormant Developmental Projects,2015 34



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify